Using the HbA1c Test Wisely in Clinical Practice

Posted on October 23, 2015 by


Upcoming webinar by the American Association for Clinical Chemistry (AACC) warns of variants and adducts that may affect accuracy of A1c tests

 

New York, NY (October 23, 2015) – An upcoming webinar hosted by the AACC will discuss potential pitfalls of the hemoglobin A1c test due to conditional interferences that can affect the accuracy of this traditional glucose test for diabetes.

The webinar will feature Randie R. Little, Ph.D, Professor, Departments of Pathology and Anatomical Sciences and Child Health and Director, Diabetes Laboratory, University of Missiouri; and , Steven D. Wittlin, M.D., Clinical Director, Endocrine-Metabolism Division and Director, Diabetes Service, University of Rochester Medical Center.

The program addresses recent changes in best practices for use of the HbA1c testing, as well as the wide availability of numerous test methods, and emphasizes the importance for lab professionals to know how to ensure the accuracy and clinical utility of HbA1c results.

HbA1c is routinely used in the management of diabetes to monitor long term glycemic control and assess the risk of developing complications. It has also recently been recommended for use in the diagnosis of diabetes, provided that the specific HbA1C test systems are of the highest performance.

And while A1C is a commonly ordered test, A1C can be a tricky proposal, including the possibility that Hb variants and adducts may affect the accuracy of the HbA1c method. Each method must be evaluated for potential interference in the presence of the most common heterozygous variants and other known interferents.*

The webinar will be held on November 4, 2015 and again on November 11. Registration is FREE. For specific times and registration follow this link:

https://www.aacc.org/store/webinars/10500/using-the-hba1c-test-wisely-in-clinical-practice—1

* Used by permission of the AACC.

 

CONTACT:

Press inquiries:
Lauren Lehman
858-437-1107
Lauren_Lehman@GlycoMark.com

Clinical/science:
Jeff Dahlen
619-540-4177
Jeff_Dahlen@GlycoMark.com